Kidney Cancer Drugs Market Report

Global and Region Kidney Cancer Drugs Market Demand & Opportunity Outlook 2022-2028

  • POSTDATE：Jul 31, 2022
  • PAGES：190
  • REPORT CODE：GMM927697
  • REPORT SUMMARY
  • TABLE OF CONTENTS

  • Kidney cancer, also known as renal cancer, is a type of cancer that starts in the cells in the kidney. The two most common types of kidney cancer are renal cell carcinoma (RCC) and transitional cell carcinoma (TCC) of the renal pelvis. These names reflect the type of cell from which the cancer developed. The different types of kidney cancer (such as RCC and TCC) develop in different ways, meaning that the diseases have different long term outcomes, and need to be staged and treated in different ways. RCC is responsible for approximately 80% of primary renal cancers, and TCC accounts the majority of the remainder.

    Biological therapies are drugs which are used to kill cancer cells or stop them from growing. Biological therapies are used to try to shrink or control advanced kidney cancer and help people to live longer. You may be given biological therapies for kidney cancer that has already spread, or is at high-risk of coming back after surgery.

    The report details the trend, potential and market size of Kidney Cancer Drugs market, and analyzes the current situation and prospects of the market from both qualitative and quantitative aspects, which can be roughly divided into three parts.

    The first part (Chapter1-7) mainly covers the qualitative analysis of Kidney Cancer Drugsmarket, defines the market attractiveness level of Kidney Cancer Drugs market through Porter's Five Forces Analysis, and summarizes the different factors in the overall environment through PEST analysis. Understand the distribution of industrial chain value in each link of industrial chain through the analysis of industrial chain structure. Thus estimate the market space of each link.

    The second part (Chapter8-12), based on the segmentation of Kidney Cancer Drugs industry, describes the types of Kidney Cancer Drugs market, the applications of major players and the market size, and deeply analyzes the current situation of the global Kidney Cancer Drugs market and the development prospects and opportunities of Kidney Cancer Drugs industry.

    The third part (Chapter14-15) includes the market positions of the major players and information on the market participants, which will help you gain a comprehensive understanding of the current competitive situation and potential growth opportunities in the market.

    As COVID-19 continues to impact the global economy in 2022, the report also considers the short - and long-term impacts of COVID-19 on the global Kidney Cancer Drugs market in Chapter 13.

    By Player:

    • AVEO Pharmaceuticals

    • ArQule

    • Cerulean Pharma

    • Amgen

    • Ono Pharmaceutical

    • Roche

    • Genentech

    • Pfizer

    • Oxford BioMedica

    • Novartis

    • Bionomics

    • Active Biotech

    • Taiwan Liposome

    • Bayer

    • Abbott Laboratories

    • GlaxoSmithKline

    • Immunicum

    • Argos Therapeutics

    • Wilex

    • Exelixis

    • Bristol-Myers Squibb

    • Tracon Pharmaceuticals

    • Onyx Therapeutics

    • Seattle Genetics

    • immatics biotechnologies

    • Prometheus Laboratories

    By Type:

    • Angiogenesis Inhibitors

    • mTOR Inhibitors

    • Monoclonal Antibodies

    • Cytokine Immunotherapy (IL-2)

    By End-User:

    • Renal cell carcinoma (RCC)

    • Transitional cell carcinoma (TCC)

    By Geography:

    • United States

    • Europe

    • China

    • Japan

    • India

    • South Korea

  • TABLE OF CONTENT

    1 Introduction

    • 1.1 Market Definition

    • 1.2 Market Segment Analysis

    • 1.3 Market Size 2022

    • 1.4 Kidney Cancer Drugs Market Outlook: Forecast for 2022 - 2028

    • 1.5 Pricing Analysis

    2 Executive Summary

    3 Kidney Cancer Drugs Market Lineage Outlook

    • 3.1 Parent Market Outlook

    • 3.2 Related/Ancillary Market Outlook

    • 3.3 Penetration & Growth Prospect Mapping, 2022

    4 Market Analysis Tools: Porter's Five Forces

    • 4.1 Supplier Power

    • 4.2 Buyer Power

    • 4.3 Substitution Threat

    • 4.4 Threat of New Entrants

    • 4.5 Competitive Rivalry

    5 Kidney Cancer Drugs Industry Analysis - PEST (Political & Legal, Economic, Social, and Technological)

    • 5.1 Political/Legal Landscape

    • 5.2 Economic Landscape

    • 5.3 Social Landscape

    • 5.4 Technology Landscape

    6 Kidney Cancer Drugs Market - Value Chain Analysis

    • 6.1 Industry's Value Chain Analysis

    • 6.2 Product Life Cycle

    • 6.3 User Perspective Analysis

    7 Region and Country-wise Kidney Cancer Drugs Market Analysis and Outlook to 2022

    • 7.1 Global Kidney Cancer Drugs Consumption (2017-2022)

    • 7.2 United States Kidney Cancer Drugs Consumption (2017-2022)

    • 7.3 Europe Kidney Cancer Drugs Consumption (2017-2022)

    • 7.4 China Kidney Cancer Drugs Consumption (2017-2022)

    • 7.5 Japan Kidney Cancer Drugs Consumption (2017-2022)

    • 7.6 India Kidney Cancer Drugs Consumption (2017-2022)

    • 7.7 South Korea Kidney Cancer Drugs Consumption (2017-2022)

    8 Region and Country-wise Kidney Cancer Drugs Market Analysis and Outlook to 2028

    • 8.1 Global Kidney Cancer Drugs Consumption Forecast (2022-2028)

    • 8.2 United States Kidney Cancer Drugs Consumption Forecast (2022-2028)

    • 8.3 Europe Kidney Cancer Drugs Consumption Forecast (2022-2028)

    • 8.4 China Kidney Cancer Drugs Consumption Forecast (2022-2028)

    • 8.5 Japan Kidney Cancer Drugs Consumption Forecast (2022-2028)

    • 8.6 India Kidney Cancer Drugs Consumption Forecast (2022-2028)

    • 8.7 South Korea Kidney Cancer Drugs Consumption Forecast (2022-2028)

    9 Global Kidney Cancer Drugs Market Outlook by Types and Applications to 2022

    • 9.1 Global Kidney Cancer Drugs Consumption and Growth Rate by Type (2017-2022)

      • 9.1.1 Global Angiogenesis Inhibitors Consumption and Growth Rate (2017-2022)

      • 9.1.2 Global mTOR Inhibitors Consumption and Growth Rate (2017-2022)

      • 9.1.3 Global Monoclonal Antibodies Consumption and Growth Rate (2017-2022)

      • 9.1.4 Global Cytokine Immunotherapy (IL-2) Consumption and Growth Rate (2017-2022)

    • 9.2 Global Kidney Cancer Drugs Consumption and Growth Rate by Application (2017-2022)

      • 9.2.1 Global Renal cell carcinoma (RCC) Consumption and Growth Rate (2017-2022)

      • 9.2.2 Global Transitional cell carcinoma (TCC) Consumption and Growth Rate (2017-2022)

    10 Global Kidney Cancer Drugs Market Outlook by Types and Applications to 2028

    • 10.1 Global Kidney Cancer Drugs Consumption Forecast and Growth Rate by Type (2022-2028)

      • 10.1.1 Global Angiogenesis Inhibitors Consumption Forecast and Growth Rate (2022-2028)

      • 10.1.2 Global mTOR Inhibitors Consumption Forecast and Growth Rate (2022-2028)

      • 10.1.3 Global Monoclonal Antibodies Consumption Forecast and Growth Rate (2022-2028)

      • 10.1.4 Global Cytokine Immunotherapy (IL-2) Consumption Forecast and Growth Rate (2022-2028)

    • 10.2 Global Kidney Cancer Drugs Consumption Forecast and Growth Rate by Application (2022-2028)

      • 10.2.1 Global Renal cell carcinoma (RCC) Consumption Forecast and Growth Rate (2022-2028)

      • 10.2.2 Global Transitional cell carcinoma (TCC) Consumption Forecast and Growth Rate (2022-2028)

    11 Global Kidney Cancer Drugs Import and Export Analysis (Top 5 Countries)

    • 11.1 Global Kidney Cancer Drugs Import by Region (Top 5 Countries) (2017-2028)

    • 11.2 Global Kidney Cancer Drugs Export by Region (Top 5 Countries) (2017-2028)

    12 Coronavirus Disease (COVID-19) Impact

    • 12.1 Industry Impact Analysis

    • 12.2 Kidney Cancer Drugs Market Outlook to 2028 - COVID-19 Affected Forecasts

    13 Competition Matrix

    • 13.1 Target Markets

    • 13.2 Comprehensive Analysis of Products in Competitive Markets

    14 Global Kidney Cancer Drugs Market Competitive Analysis

    • 14.1 AVEO Pharmaceuticals

      • 14.1.1 AVEO Pharmaceuticals Company Details

      • 14.1.2 AVEO Pharmaceuticals Kidney Cancer Drugs Sales, Price, Value and Gross Profit (2017-2022)

      • 14.1.3 AVEO Pharmaceuticals Kidney Cancer Drugs Product and Service

    • 14.2 ArQule

      • 14.2.1 ArQule Company Details

      • 14.2.2 ArQule Kidney Cancer Drugs Sales, Price, Value and Gross Profit (2017-2022)

      • 14.2.3 ArQule Kidney Cancer Drugs Product and Service

    • 14.3 Cerulean Pharma

      • 14.3.1 Cerulean Pharma Company Details

      • 14.3.2 Cerulean Pharma Kidney Cancer Drugs Sales, Price, Value and Gross Profit (2017-2022)

      • 14.3.3 Cerulean Pharma Kidney Cancer Drugs Product and Service

    • 14.4 Amgen

      • 14.4.1 Amgen Company Details

      • 14.4.2 Amgen Kidney Cancer Drugs Sales, Price, Value and Gross Profit (2017-2022)

      • 14.4.3 Amgen Kidney Cancer Drugs Product and Service

    • 14.5 Ono Pharmaceutical

      • 14.5.1 Ono Pharmaceutical Company Details

      • 14.5.2 Ono Pharmaceutical Kidney Cancer Drugs Sales, Price, Value and Gross Profit (2017-2022)

      • 14.5.3 Ono Pharmaceutical Kidney Cancer Drugs Product and Service

    • 14.6 Roche

      • 14.6.1 Roche Company Details

      • 14.6.2 Roche Kidney Cancer Drugs Sales, Price, Value and Gross Profit (2017-2022)

      • 14.6.3 Roche Kidney Cancer Drugs Product and Service

    • 14.7 Genentech

      • 14.7.1 Genentech Company Details

      • 14.7.2 Genentech Kidney Cancer Drugs Sales, Price, Value and Gross Profit (2017-2022)

      • 14.7.3 Genentech Kidney Cancer Drugs Product and Service

    • 14.8 Pfizer

      • 14.8.1 Pfizer Company Details

      • 14.8.2 Pfizer Kidney Cancer Drugs Sales, Price, Value and Gross Profit (2017-2022)

      • 14.8.3 Pfizer Kidney Cancer Drugs Product and Service

    • 14.9 Oxford BioMedica

      • 14.9.1 Oxford BioMedica Company Details

      • 14.9.2 Oxford BioMedica Kidney Cancer Drugs Sales, Price, Value and Gross Profit (2017-2022)

      • 14.9.3 Oxford BioMedica Kidney Cancer Drugs Product and Service

    • 14.10 Novartis

      • 14.10.1 Novartis Company Details

      • 14.10.2 Novartis Kidney Cancer Drugs Sales, Price, Value and Gross Profit (2017-2022)

      • 14.10.3 Novartis Kidney Cancer Drugs Product and Service

    • 14.11 Bionomics

      • 14.11.1 Bionomics Company Details

      • 14.11.2 Bionomics Kidney Cancer Drugs Sales, Price, Value and Gross Profit (2017-2022)

      • 14.11.3 Bionomics Kidney Cancer Drugs Product and Service

    • 14.12 Active Biotech

      • 14.12.1 Active Biotech Company Details

      • 14.12.2 Active Biotech Kidney Cancer Drugs Sales, Price, Value and Gross Profit (2017-2022)

      • 14.12.3 Active Biotech Kidney Cancer Drugs Product and Service

    • 14.13 Taiwan Liposome

      • 14.13.1 Taiwan Liposome Company Details

      • 14.13.2 Taiwan Liposome Kidney Cancer Drugs Sales, Price, Value and Gross Profit (2017-2022)

      • 14.13.3 Taiwan Liposome Kidney Cancer Drugs Product and Service

    • 14.14 Bayer

      • 14.14.1 Bayer Company Details

      • 14.14.2 Bayer Kidney Cancer Drugs Sales, Price, Value and Gross Profit (2017-2022)

      • 14.14.3 Bayer Kidney Cancer Drugs Product and Service

    • 14.15 Abbott Laboratories

      • 14.15.1 Abbott Laboratories Company Details

      • 14.15.2 Abbott Laboratories Kidney Cancer Drugs Sales, Price, Value and Gross Profit (2017-2022)

      • 14.15.3 Abbott Laboratories Kidney Cancer Drugs Product and Service

    • 14.16 GlaxoSmithKline

      • 14.16.1 GlaxoSmithKline Company Details

      • 14.16.2 GlaxoSmithKline Kidney Cancer Drugs Sales, Price, Value and Gross Profit (2017-2022)

      • 14.16.3 GlaxoSmithKline Kidney Cancer Drugs Product and Service

    • 14.17 Immunicum

      • 14.17.1 Immunicum Company Details

      • 14.17.2 Immunicum Kidney Cancer Drugs Sales, Price, Value and Gross Profit (2017-2022)

      • 14.17.3 Immunicum Kidney Cancer Drugs Product and Service

    • 14.18 Argos Therapeutics

      • 14.18.1 Argos Therapeutics Company Details

      • 14.18.2 Argos Therapeutics Kidney Cancer Drugs Sales, Price, Value and Gross Profit (2017-2022)

      • 14.18.3 Argos Therapeutics Kidney Cancer Drugs Product and Service

    • 14.19 Wilex

      • 14.19.1 Wilex Company Details

      • 14.19.2 Wilex Kidney Cancer Drugs Sales, Price, Value and Gross Profit (2017-2022)

      • 14.19.3 Wilex Kidney Cancer Drugs Product and Service

    • 14.20 Exelixis

      • 14.20.1 Exelixis Company Details

      • 14.20.2 Exelixis Kidney Cancer Drugs Sales, Price, Value and Gross Profit (2017-2022)

      • 14.20.3 Exelixis Kidney Cancer Drugs Product and Service

    • 14.21 Bristol-Myers Squibb

      • 14.21.1 Bristol-Myers Squibb Company Details

      • 14.21.2 Bristol-Myers Squibb Kidney Cancer Drugs Sales, Price, Value and Gross Profit (2017-2022)

      • 14.21.3 Bristol-Myers Squibb Kidney Cancer Drugs Product and Service

    • 14.22 Tracon Pharmaceuticals

      • 14.22.1 Tracon Pharmaceuticals Company Details

      • 14.22.2 Tracon Pharmaceuticals Kidney Cancer Drugs Sales, Price, Value and Gross Profit (2017-2022)

      • 14.22.3 Tracon Pharmaceuticals Kidney Cancer Drugs Product and Service

    • 14.23 Onyx Therapeutics

      • 14.23.1 Onyx Therapeutics Company Details

      • 14.23.2 Onyx Therapeutics Kidney Cancer Drugs Sales, Price, Value and Gross Profit (2017-2022)

      • 14.23.3 Onyx Therapeutics Kidney Cancer Drugs Product and Service

    • 14.24 Seattle Genetics

      • 14.24.1 Seattle Genetics Company Details

      • 14.24.2 Seattle Genetics Kidney Cancer Drugs Sales, Price, Value and Gross Profit (2017-2022)

      • 14.24.3 Seattle Genetics Kidney Cancer Drugs Product and Service

    • 14.25 immatics biotechnologies

      • 14.25.1 immatics biotechnologies Company Details

      • 14.25.2 immatics biotechnologies Kidney Cancer Drugs Sales, Price, Value and Gross Profit (2017-2022)

      • 14.25.3 immatics biotechnologies Kidney Cancer Drugs Product and Service

    • 14.26 Prometheus Laboratories

      • 14.26.1 Prometheus Laboratories Company Details

      • 14.26.2 Prometheus Laboratories Kidney Cancer Drugs Sales, Price, Value and Gross Profit (2017-2022)

      • 14.26.3 Prometheus Laboratories Kidney Cancer Drugs Product and Service

    15 Appendix


    TABLE OF CHARTS

    • Table Definition of Kidney Cancer Drugs

    • Figure Kidney Cancer Drugs Picture

    • Table Global Kidney Cancer Drugs Market Size and Forecast 2022 - 2028 (USD million)

    • Figure Global Kidney Cancer Drugs Market Size and Forecast 2022 - 2028 (USD million)

    • Figure Global Kidney Cancer Drugs Market: Year-over-year Growth 2022 - 2028 (%)

    • Table Parent Market Analysis

    • Figure Parent Market Price

    • Table Related/Ancillary Market Outlook Analysis

    • Table Supplier Power Analysis

    • Table Buyer Power Analysis

    • Table Substitution Threat Analysis

    • Table Threat of New Entrants Analysis

    • Table Competitive Rivalry Analysis

    • Figure Global Kidney Cancer Drugs Consumption by Country (2017-2022)

    • Figure United States Kidney Cancer Drugs Consumption and Growth Rate (2017-2022)

    • Table Europe Kidney Cancer Drugs Consumption and Growth Rate (2017-2022)

    • Figure China Kidney Cancer Drugs Consumption and Growth Rate (2017-2022)

    • Figure Japan Kidney Cancer Drugs Consumption and Growth Rate (2017-2022)

    • Figure India Kidney Cancer Drugs Consumption and Growth Rate (2017-2022)

    • Figure South Korea Kidney Cancer Drugs Consumption and Growth Rate (2017-2022)

    • Figure Global Kidney Cancer Drugs Consumption Forecast by Country (2022-2028)

    • Figure United States Kidney Cancer Drugs Consumption Forecast and Growth Rate (2022-2028)

    • Table Europe Kidney Cancer Drugs Consumption Forecast and Growth Rate (2022-2028)

    • Figure China Kidney Cancer Drugs Consumption Forecast and Growth Rate (2022-2028)

    • Figure Japan Kidney Cancer Drugs Consumption Forecast and Growth Rate (2022-2028)

    • Figure India Kidney Cancer Drugs Consumption Forecast and Growth Rate (2022-2028)

    • Figure South Korea Kidney Cancer Drugs Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Angiogenesis Inhibitors Consumption and Growth Rate (2017-2022)

    • Figure Global mTOR Inhibitors Consumption and Growth Rate (2017-2022)

    • Figure Global Monoclonal Antibodies Consumption and Growth Rate (2017-2022)

    • Figure Global Cytokine Immunotherapy (IL-2) Consumption and Growth Rate (2017-2022)

    • Figure Global Renal cell carcinoma (RCC) Consumption and Growth Rate (2017-2022)

    • Figure Global Transitional cell carcinoma (TCC) Consumption and Growth Rate (2017-2022)

    • Figure Global Angiogenesis Inhibitors Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global mTOR Inhibitors Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Monoclonal Antibodies Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Cytokine Immunotherapy (IL-2) Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Renal cell carcinoma (RCC) Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Transitional cell carcinoma (TCC) Consumption Forecast and Growth Rate (2022-2028)

    • Table Global Kidney Cancer Drugs Import by Region (Top 5 Countries) (2017-2028)

    • Table Global Kidney Cancer Drugs Export by Region (Top 5 Countries) (2017-2028)

    • Table AVEO Pharmaceuticals (Foundation Year, Company Profile and etc.)

    • Table AVEO Pharmaceuticals Kidney Cancer Drugs Sales, Price, Value and Gross Profit (2017-2022)

    • Table AVEO Pharmaceuticals Kidney Cancer Drugs Product and Service

    • Table ArQule (Foundation Year, Company Profile and etc.)

    • Table ArQule Kidney Cancer Drugs Sales, Price, Value and Gross Profit (2017-2022)

    • Table ArQule Kidney Cancer Drugs Product and Service

    • Table Cerulean Pharma (Foundation Year, Company Profile and etc.)

    • Table Cerulean Pharma Kidney Cancer Drugs Sales, Price, Value and Gross Profit (2017-2022)

    • Table Cerulean Pharma Kidney Cancer Drugs Product and Service

    • Table Amgen (Foundation Year, Company Profile and etc.)

    • Table Amgen Kidney Cancer Drugs Sales, Price, Value and Gross Profit (2017-2022)

    • Table Amgen Kidney Cancer Drugs Product and Service

    • Table Ono Pharmaceutical (Foundation Year, Company Profile and etc.)

    • Table Ono Pharmaceutical Kidney Cancer Drugs Sales, Price, Value and Gross Profit (2017-2022)

    • Table Ono Pharmaceutical Kidney Cancer Drugs Product and Service

    • Table Roche (Foundation Year, Company Profile and etc.)

    • Table Roche Kidney Cancer Drugs Sales, Price, Value and Gross Profit (2017-2022)

    • Table Roche Kidney Cancer Drugs Product and Service

    • Table Genentech (Foundation Year, Company Profile and etc.)

    • Table Genentech Kidney Cancer Drugs Sales, Price, Value and Gross Profit (2017-2022)

    • Table Genentech Kidney Cancer Drugs Product and Service

    • Table Pfizer (Foundation Year, Company Profile and etc.)

    • Table Pfizer Kidney Cancer Drugs Sales, Price, Value and Gross Profit (2017-2022)

    • Table Pfizer Kidney Cancer Drugs Product and Service

    • Table Oxford BioMedica (Foundation Year, Company Profile and etc.)

    • Table Oxford BioMedica Kidney Cancer Drugs Sales, Price, Value and Gross Profit (2017-2022)

    • Table Oxford BioMedica Kidney Cancer Drugs Product and Service

    • Table Novartis (Foundation Year, Company Profile and etc.)

    • Table Novartis Kidney Cancer Drugs Sales, Price, Value and Gross Profit (2017-2022)

    • Table Novartis Kidney Cancer Drugs Product and Service

    • Table Bionomics (Foundation Year, Company Profile and etc.)

    • Table Bionomics Kidney Cancer Drugs Sales, Price, Value and Gross Profit (2017-2022)

    • Table Bionomics Kidney Cancer Drugs Product and Service

    • Table Active Biotech (Foundation Year, Company Profile and etc.)

    • Table Active Biotech Kidney Cancer Drugs Sales, Price, Value and Gross Profit (2017-2022)

    • Table Active Biotech Kidney Cancer Drugs Product and Service

    • Table Taiwan Liposome (Foundation Year, Company Profile and etc.)

    • Table Taiwan Liposome Kidney Cancer Drugs Sales, Price, Value and Gross Profit (2017-2022)

    • Table Taiwan Liposome Kidney Cancer Drugs Product and Service

    • Table Bayer (Foundation Year, Company Profile and etc.)

    • Table Bayer Kidney Cancer Drugs Sales, Price, Value and Gross Profit (2017-2022)

    • Table Bayer Kidney Cancer Drugs Product and Service

    • Table Abbott Laboratories (Foundation Year, Company Profile and etc.)

    • Table Abbott Laboratories Kidney Cancer Drugs Sales, Price, Value and Gross Profit (2017-2022)

    • Table Abbott Laboratories Kidney Cancer Drugs Product and Service

    • Table GlaxoSmithKline (Foundation Year, Company Profile and etc.)

    • Table GlaxoSmithKline Kidney Cancer Drugs Sales, Price, Value and Gross Profit (2017-2022)

    • Table GlaxoSmithKline Kidney Cancer Drugs Product and Service

    • Table Immunicum (Foundation Year, Company Profile and etc.)

    • Table Immunicum Kidney Cancer Drugs Sales, Price, Value and Gross Profit (2017-2022)

    • Table Immunicum Kidney Cancer Drugs Product and Service

    • Table Argos Therapeutics (Foundation Year, Company Profile and etc.)

    • Table Argos Therapeutics Kidney Cancer Drugs Sales, Price, Value and Gross Profit (2017-2022)

    • Table Argos Therapeutics Kidney Cancer Drugs Product and Service

    • Table Wilex (Foundation Year, Company Profile and etc.)

    • Table Wilex Kidney Cancer Drugs Sales, Price, Value and Gross Profit (2017-2022)

    • Table Wilex Kidney Cancer Drugs Product and Service

    • Table Exelixis (Foundation Year, Company Profile and etc.)

    • Table Exelixis Kidney Cancer Drugs Sales, Price, Value and Gross Profit (2017-2022)

    • Table Exelixis Kidney Cancer Drugs Product and Service

    • Table Bristol-Myers Squibb (Foundation Year, Company Profile and etc.)

    • Table Bristol-Myers Squibb Kidney Cancer Drugs Sales, Price, Value and Gross Profit (2017-2022)

    • Table Bristol-Myers Squibb Kidney Cancer Drugs Product and Service

    • Table Tracon Pharmaceuticals (Foundation Year, Company Profile and etc.)

    • Table Tracon Pharmaceuticals Kidney Cancer Drugs Sales, Price, Value and Gross Profit (2017-2022)

    • Table Tracon Pharmaceuticals Kidney Cancer Drugs Product and Service

    • Table Onyx Therapeutics (Foundation Year, Company Profile and etc.)

    • Table Onyx Therapeutics Kidney Cancer Drugs Sales, Price, Value and Gross Profit (2017-2022)

    • Table Onyx Therapeutics Kidney Cancer Drugs Product and Service

    • Table Seattle Genetics (Foundation Year, Company Profile and etc.)

    • Table Seattle Genetics Kidney Cancer Drugs Sales, Price, Value and Gross Profit (2017-2022)

    • Table Seattle Genetics Kidney Cancer Drugs Product and Service

    • Table immatics biotechnologies (Foundation Year, Company Profile and etc.)

    • Table immatics biotechnologies Kidney Cancer Drugs Sales, Price, Value and Gross Profit (2017-2022)

    • Table immatics biotechnologies Kidney Cancer Drugs Product and Service

    • Table Prometheus Laboratories (Foundation Year, Company Profile and etc.)

    • Table Prometheus Laboratories Kidney Cancer Drugs Sales, Price, Value and Gross Profit (2017-2022)

    • Table Prometheus Laboratories Kidney Cancer Drugs Product and Service


Report Version Choose

Report

BUY NOW

Our Customers

Beyond grateful for the confidence and support from all partners and customers.A win-win situation is our ultimate pursuit.

Beyond Consulting, Future is Feasible

We provide more professional and intelligent market reports to complement your business decisions.

CONTACT US